Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Alibaba Shares Fall as AI Spending Hits Profit 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Add as a preferred source on Google
NEW YORK, May 08, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN) who purchased shares between August 13, 2014 and March 12, 2018. The action, which was filed in the United States District Court for the District of Utah, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
Shareholders have until June 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/myriad-genetics-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
